Improved survival with ipilimumab in patients with metastatic melanoma.

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ

Open source

DOI: 10.1056/nejmoa1003466
Published: 2010 Aug 19
Container: The New England journal of medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa1003466,
  title = {Improved survival with ipilimumab in patients with metastatic melanoma.},
  author = {Hodi FS and O'Day SJ and McDermott DF and Weber RW and Sosman JA and Haanen JB and Gonzalez R and Robert C and Schadendorf D and Hassel JC and Akerley W and van den Eertwegh AJ and Lutzky J and Lorigan P and Vaubel JM and Linette GP and Hogg D and Ottensmeier CH and Lebbé C and Peschel C and Quirt I and Clark JI and Wolchok JD and Weber JS and Tian J and Yellin MJ and Nichol GM and Hoos A and Urba WJ},
  year = {2010},
  journal = {The New England journal of medicine},
  doi = {10.1056/nejmoa1003466},
  url = {https://doi.org/10.1056/nejmoa1003466}
}

RIS

TY  - JOUR
TI  - Improved survival with ipilimumab in patients with metastatic melanoma.
AU  - Hodi FS
AU  - O'Day SJ
AU  - McDermott DF
AU  - Weber RW
AU  - Sosman JA
AU  - Haanen JB
AU  - Gonzalez R
AU  - Robert C
AU  - Schadendorf D
AU  - Hassel JC
AU  - Akerley W
AU  - van den Eertwegh AJ
AU  - Lutzky J
AU  - Lorigan P
AU  - Vaubel JM
AU  - Linette GP
AU  - Hogg D
AU  - Ottensmeier CH
AU  - Lebbé C
AU  - Peschel C
AU  - Quirt I
AU  - Clark JI
AU  - Wolchok JD
AU  - Weber JS
AU  - Tian J
AU  - Yellin MJ
AU  - Nichol GM
AU  - Hoos A
AU  - Urba WJ
PY  - 2010
JO  - The New England journal of medicine
DO  - 10.1056/nejmoa1003466
UR  - https://doi.org/10.1056/nejmoa1003466
ER  -

APA

FS, H., SJ, O., DF, M., RW, W., JA, S., JB, H., R, G., C, R., D, S., JC, H., W, A., AJ, V. D. E., J, L., P, L., JM, V., GP, L., D, H., CH, O., C, L., C, P., I, Q., JI, C., JD, W., JS, W., J, T., MJ, Y., GM, N., A, H., & WJ, U. (2010). Improved survival with ipilimumab in patients with metastatic melanoma.. The New England journal of medicine. https://doi.org/10.1056/nejmoa1003466

Source records

pubmed · retrieved 2026-09-25T05:41:54.392Z